Moxifloxacin dosing in postbariatric surgery patients

Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium, Department of Anesthesiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, Department of Anesthesia, Ghent University, Ghent, Heymans Institute of Pharmacology, Ghent University, Ghent, Department Endocrinology and Metabolic Diseases, Ghent University Hospital, Ghent and Department of Critical Care Medicine,

[1]  D. Brocks,et al.  The effects of gastric bypass surgery on drug absorption and pharmacokinetics , 2012, Expert opinion on drug metabolism & toxicology.

[2]  D. Ashcroft,et al.  Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. , 2012, British journal of clinical pharmacology.

[3]  Arya M. Sharma,et al.  Effect of gastric bypass surgery on azithromycin oral bioavailability. , 2012, The Journal of antimicrobial chemotherapy.

[4]  T. Wiemken,et al.  Global Changes in the Epidemiology of Community-Acquired Pneumonia , 2012, Seminars in Respiratory and Critical Care Medicine.

[5]  P. Grosjean,et al.  Reevaluation of Moxifloxacin Pharmacokinetics and Their Direct Effect on the QT Interval , 2012, Journal of clinical pharmacology.

[6]  L. V. Van Bortel,et al.  Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. , 2012, The Journal of antimicrobial chemotherapy.

[7]  Christine E Garnett,et al.  Population Pharmacokinetic and Concentration—QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies , 2011, Journal of clinical pharmacology.

[8]  M. Nikolaou,et al.  Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. , 2011, The Journal of antimicrobial chemotherapy.

[9]  K. Colpaert,et al.  Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  France Mentré,et al.  Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R , 2008, Comput. Methods Programs Biomed..

[11]  Mats O. Karlsson,et al.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  Xh Huang,et al.  Pharmacokinetic-Pharmacodynamic Modeling and Simulation. , 2007 .

[13]  O. Cars,et al.  Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. , 2006, The Journal of antimicrobial chemotherapy.

[14]  H. Stass,et al.  The Integrated Use of Pharmacokinetic and Pharmacodynamic Models for the Definition of Breakpoints , 2005, Infection.

[15]  S. Zinner,et al.  Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones , 2005, Antimicrobial Agents and Chemotherapy.

[16]  A. Ferrara.  New Fluoroquinolones in Lower Respiratory Tract Infections and Emerging Patterns of Pneumococcal Resistance , 2005, Infection.

[17]  Xilin Zhao,et al.  Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. , 2003, The Journal of antimicrobial chemotherapy.

[18]  S. Urien,et al.  Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia , 2003, Clinical pharmacology and therapeutics.

[19]  S. Duffull,et al.  Caution when lean body weight is used as a size descriptor for obese subjects. , 2002, Clinical pharmacology and therapeutics.

[20]  S. Zinner,et al.  AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. , 2002, The Journal of antimicrobial chemotherapy.

[21]  D. Hoban,et al.  In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. , 2001, The Journal of antimicrobial chemotherapy.

[22]  M. Klepser,et al.  Comparative Bactericidal Activities of Ciprofloxacin, Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Streptococcus pneumoniae in a Dynamic In Vitro Model , 2001, Antimicrobial Agents and Chemotherapy.

[23]  H. Stass,et al.  Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects , 1998, Antimicrobial Agents and Chemotherapy.